CN115151262A - 基因疗法的心外膜递送 - Google Patents

基因疗法的心外膜递送 Download PDF

Info

Publication number
CN115151262A
CN115151262A CN202080083691.XA CN202080083691A CN115151262A CN 115151262 A CN115151262 A CN 115151262A CN 202080083691 A CN202080083691 A CN 202080083691A CN 115151262 A CN115151262 A CN 115151262A
Authority
CN
China
Prior art keywords
subject
heart
vegf
injection
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080083691.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·莱因哈特
T·罗森加德
R·克里斯特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silcole Therapeutics
Baylor College of Medicine
Cornell University
Original Assignee
Silcole Therapeutics
Baylor College of Medicine
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silcole Therapeutics, Baylor College of Medicine, Cornell University filed Critical Silcole Therapeutics
Publication of CN115151262A publication Critical patent/CN115151262A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080083691.XA 2019-10-09 2020-10-09 基因疗法的心外膜递送 Pending CN115151262A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962912958P 2019-10-09 2019-10-09
US62/912,958 2019-10-09
PCT/US2020/055082 WO2021072272A1 (en) 2019-10-09 2020-10-09 Epicardial delivery of gene therapy

Publications (1)

Publication Number Publication Date
CN115151262A true CN115151262A (zh) 2022-10-04

Family

ID=75437778

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080083691.XA Pending CN115151262A (zh) 2019-10-09 2020-10-09 基因疗法的心外膜递送

Country Status (6)

Country Link
US (1) US20240115732A1 (https=)
EP (1) EP4041192A4 (https=)
JP (1) JP2022551911A (https=)
CN (1) CN115151262A (https=)
CA (1) CA3153845A1 (https=)
WO (1) WO2021072272A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024233783A1 (en) * 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032859A1 (en) * 1997-01-29 1998-07-30 Cornell Research Foundation, Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
WO2004045513A2 (en) * 2002-11-15 2004-06-03 Genvec, Inc. Coronary artery disease treatment
US20050271634A1 (en) * 2000-04-06 2005-12-08 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
US20060084622A1 (en) * 1998-03-11 2006-04-20 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
WO2014071199A1 (en) * 2012-11-02 2014-05-08 Cornell University Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197324B1 (en) * 1997-12-18 2001-03-06 C. R. Bard, Inc. System and methods for local delivery of an agent
EP2925863B1 (en) * 2012-11-30 2020-07-15 Vestion Inc. Cardiac stem cells and methods of identifying and using the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032859A1 (en) * 1997-01-29 1998-07-30 Cornell Research Foundation, Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
CA2278621A1 (en) * 1997-01-29 1998-07-30 Cornell Research Foundation, Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
US20060084622A1 (en) * 1998-03-11 2006-04-20 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
US20050271634A1 (en) * 2000-04-06 2005-12-08 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
WO2004045513A2 (en) * 2002-11-15 2004-06-03 Genvec, Inc. Coronary artery disease treatment
WO2014071199A1 (en) * 2012-11-02 2014-05-08 Cornell University Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium

Also Published As

Publication number Publication date
WO2021072272A1 (en) 2021-04-15
JP2022551911A (ja) 2022-12-14
US20240115732A1 (en) 2024-04-11
EP4041192A1 (en) 2022-08-17
EP4041192A4 (en) 2023-11-08
CA3153845A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
DE69827021T2 (de) An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese
JP3961019B2 (ja) 遺伝子転移媒介の血管形成療法
CN101683533A (zh) 基因转移介导的血管形成疗法
WO2005051432A1 (en) Therapeutic regimen for treating cancer
Post et al. Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation
Sen et al. Efficiency, efficacy, and adverse effects of adenovirus-vs. liposome-mediated gene therapy in cardiac allografts
CA2289600C (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
JP2003513942A (ja) インビボ遺伝子送達による心血管疾患を処理するための技術および組成物
Li et al. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model
US6867022B1 (en) Replication deficient adenovirus vectors and methods of making and using them
CN115151262A (zh) 基因疗法的心外膜递送
JP2002502885A (ja) 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ
US7829329B2 (en) Adenoviral vectors for treating disease
HK40077535A (en) Epicardial delivery of gene therapy
US20050191278A1 (en) Coronary artery disease treatment
Ricci et al. Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted hearts
KR20090035711A (ko) 유전자 치료를 위한 아데노-관련 바이러스 벡터의 전방 심외막 관상에의 연장 주입
Bowles et al. Prospects for adenovirus-mediated gene therapy of inherited diseases of the myocardium
WO1996040195A1 (en) Gene therapy for myocardial ischemia
Docherty Adenovirus Mediated Gene Transfer of Skeletal Troponin C to Myocardium
Khamis Hemodynamic assessment of septic mice deficient in inducible nitric oxide synthase demonstrates improved myocardial performance
Tao et al. 66. Cardiac-Specific and Hypoxia-Inducible VEGF165 and Angiopoietin-1 Expression Induces Angiogenesis and Improves Myocardial Perfusion in Pig

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077535

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221004